L-DOPA sodium (Synonyms: Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium)

Cat. No.: HY-N0304A: FAQs
Data Sheet Handling Instructions

Molarity Calculator

L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research.

For research use only. We do not sell to patients.

L-DOPA sodium Chemical Structure

CAS No. : 63302-01-2

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of L-DOPA sodium:

L-DOPA

Other Forms of L-DOPA sodium:

L-DOPA In-stock

19 Publications Citing Use of MCE L-DOPA sodium

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Dopamine Receptor Isoform Specific Products:

View All Isoforms

Dopamine Receptor D₁ Receptor D₂ Receptor D₃ Receptor D₄ Receptor D₅ Receptor

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Human Endogenous Metabolite

In Vivo

L-DOPA can be used to create movement disorder models. In adult common marmosets, after oral administration of L-DOPA (20/5 mg/kg), the T_max in plasma is 30 minutes, and the T_max in striatal extracellular fluid (ECF) is 60-90 minutes. The mean C_max of L-DOPA in plasma is 20.3 μM, while the mean C_max in striatal ECF is 442.9 nM, representing about 2.2% of the plasma level^[6].

Induction of dyskinesia model^[5]

Background

L-DOPA-induced dyskinesia results from a pulsatile stimulation of brain dopamine (DA) receptors, triggering a complex cascade of molecular and synaptic alterations within the basal ganglia^[5].

Specific Mmodeling Methods

Mice: C57Bl/6 mice • male • 8 weeks (period: 21 days)
Administration: 20 mg/kg • ip • once daily for 21 days

Note

(1) sustained unilateral 6-OHDA injections in the striatum before starting treatment.
(2) Injection volume is 10mL/kg body weight.

Modeling Indicators

Behavioral changes: Shows developed abnormal involuntary movements (AIMs) affecting the head, trunk and forelimb on the side contralateral to the lesion.

Correlated Product(s): Oxidopamine hydrochloride (HY-B1081)

Opposite Product(s): Oxidopamine hydrobromide (HY-B1081A)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice (7-week-old)^[3]
Dosage:	20 mg/kg
Administration:	Orally
Result:	Reduced Rotenone-induced motor dysfunction.

Animal Model:	Sprague-Dawley rats^[4]
Dosage:	10, 30, 50, 70, and 100 mg/kg
Administration:	Orally
Result:	Reverses tactile, cold and heat allodynia in neuropathic rat without any side effect.

Clinical Trial

Molecular Weight

219.17

Formula

C₉H₁₀NNaO₄

CAS No.

63302-01-2

SMILES

O=C([C@H](CC1=CC=C(C(O)=C1)O)N)O[Na]

Structure Classification

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10. [Content Brief]

[2]. Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(4):273-80. Epub 2007 Nov 7. [Content Brief]

[3]. Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237. [Content Brief]

[4]. Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5. [Content Brief]

[5]. M Lundblad, et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol. 2005 Jul;194(1):66-75. [Content Brief]

[6]. Jie Zhang, et al. Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. Brain Res. 2003 Dec 12;993(1-2):54-8. [Content Brief]

L-DOPA sodium Related Classifications

Neurological Disease

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

L-DOPA63302-01-2Levodopa3,4-DihydroxyphenylalanineDopamine ReceptorEndogenous MetaboliteOrallyprecursorneurotransmittersdopamineblood-brainbarrieranti-allodynicParkinsonInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks